In the ER-positive/HER2-positive breast cancer subgroup, several therapeutic strategies are currently under active investigation, including combinations such as aromatase inhibitors with lapatinib, an anti-HER2 tyrosine kinase inhibitor [16], and fulvestrant with trastuzumab [17]. The gene discussed is ERBB2; the disease is breast carcinoma.